Cancer therapeutic antibodies come of age: Targeting minimal residual disease
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Ten years after the first clinical application of Rituximab, an anti‐CD20 recombinant monoclonal antibody, immunotherapy has become common practice in oncology wards. Thanks to the great diversity of the immune system and the powerful methodology of genetic engineering, the pharmacologic potential of antibody‐based therapy is far from exhaustion. The recent application of Trastuzumab, an antibody to a receptor tyrosine kinase, in adjuvant breast cancer therapy marks the beginning of a new phase in cancer treatment. Here we discuss molecular mechanisms of antibody‐based therapy, the emerging ability to target minimal disease and the therapeutic potential of combining antibodies with other modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Klapper, L. N., Glathe, S., Vaisman, N., Hynes, N. E., Andrews, G. C., Sela, M., & Yarden, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4995 · Cited by 455
Self-citationCarnahan, J., Stein, R., Qu, Z., Hess, K., Cesano, A., Hansen, H. J., & Goldenberg, D. M. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.05.007 · Cited by 175
Cited by
Derailed endocytosis: an emerging feature of cancer
Mosesson, Y., Mills, G. B., & Yarden, Y. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2521 · Cited by 718
Self-citationRoles for Growth Factors in Cancer Progression
Witsch, E., Sela, M., & Yarden, Y. (2010) · Physiology · doi:10.1152/physiol.00045.2009 · Cited by 526
Self-citationMellman, I., & Yarden, Y. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016949 · Cited by 394
Self-citationWang, M., Cang, Z., & Wei, G.-W. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-0149-6 · Cited by 202
Deep geometric representations for modeling effects of mutations on protein-protein binding affinity
Liu, X., Luo, Y., Li, P., Song, S., & Peng, J. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009284 · Cited by 140
“The ability of Ab to bind to a wide variety of targets in a specific and selective manner has been making antibody therapy wide used for a broad range of diseases including several types of cancer (Ben-Kasus et al., 2007) and viral infection (Barouch et al.”
Background
Metadata
- Authors
- Ben-Kasus, T., Schechter, B., Sela, M., & Yarden, Y.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2007-03-14
- Volume
- 1
- Issue
- 1
- Pages
- 42-54
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2138449457
- Cited by
- 59
- References
- 5
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.